Fibrogen Stock Today
| FGEN Stock | USD 0.42 0.03 7.69% |
Performance7 of 100
| Odds Of DistressOver 71
|
FibroGen is selling at 0.42 as of the 30th of November 2024; that is 7.69 percent increase since the beginning of the trading day. The stock's open price was 0.39. FibroGen has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for FibroGen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of October 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of November 2014 | Category Healthcare | Classification Health Care |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 100.77 M outstanding shares of which 3.9 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover. More on FibroGen
Moving against FibroGen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
FibroGen Stock Highlights
| CEO Director | Thane Wettig | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsFibroGen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand FibroGen's financial leverage. It provides some insight into what part of FibroGen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FibroGen (FGEN) is traded on NASDAQ Exchange in USA. It is located in 409 Illinois Street, San Francisco, CA, United States, 94158 and employs 486 people. FibroGen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.2 M. FibroGen conducts business under Biotechnology sector and is part of Health Care industry. The entity has 100.77 M outstanding shares of which 3.9 M shares are currently shorted by private and institutional investors with about 3.27 trading days to cover.
FibroGen currently holds about 438.13 M in cash with (315.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check FibroGen Probability Of Bankruptcy
Ownership AllocationFibroGen holds a total of 100.77 Million outstanding shares. Over half of FibroGen's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check FibroGen Ownership Details
FibroGen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.1 M | |
| Assenagon Asset Management Sa | 2024-09-30 | 767.7 K | |
| Renaissance Technologies Corp | 2024-09-30 | 753.1 K | |
| Two Sigma Investments Llc | 2024-09-30 | 505.5 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 483.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 473 K | |
| Jane Street Group Llc | 2024-06-30 | 450 K | |
| State Street Corp | 2024-06-30 | 389.9 K | |
| Fmr Inc | 2024-09-30 | 383.3 K | |
| Primecap Management Company | 2024-09-30 | 9.9 M | |
| Armistice Capital, Llc | 2024-09-30 | 6.8 M |
FibroGen Historical Income Statement
FibroGen Stock Against Markets
FibroGen Corporate Management
| Kirk MBA | Chief Officer | Profile | |
| Rahul Kaushik | Technical Development | Profile | |
| Mr JD | Chief Officer | Profile | |
| Enrique Conterno | CEO Director | Profile | |
| Barry Berkowitz | Founder | Profile | |
| Christine Chung | Senior Operations | Profile | |
| David DeLucia | Vice Relations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.